Artes Medical Enforces Its Patent Rights Against Aventis in both Europe and the United States.SAN DIEGO -- Artes Medical, Inc., a privately-held specialty pharmaceutical and medical device company, today announced that it has filed an opposition to Aventis Pharmaceutical Holdings, Inc.'s European Patent No. 0969833, issued November 12, 2003. This patent relates to the injectable microsphere Not to be confused with Glass microphere. This article largely refers to micropheres or protein protocells as small spherical units postulated by some scientists as a key stage in the origin of life. implant technology used in its injectable skin fillers with the brand names Sculptra and Newfill. On August 3, 2004, Sculptra received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval for the correction of facial fat loss in people with human immunodeficiency virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. (HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ) infection. The opposition requests that the Aventis patent be revoked in its entirety as it fails to show novel and inventive steps when compared to Artes' United States Patent No. 5,344,452, issued September 6, 1994, and other patents and prior art. The opposition was filed in Munich, Germany. Artes intends to prosecute the opposition vigorously. In addition, Artes has filed an application for re-examination of Aventis' United States Patent No. 6,716,251, issued April 6, 2004, on substantially the same grounds. The request for re-examination of Aventis' United States patent was filed with the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property . Artes Medical USA, Inc. Artes Medical is a specialty pharmaceutical and medical device company focused on the development of new and innovative products for the aesthetic surgery market. The company's lead product ArteFill is a unique permanent injectable dermal filler administered by company-trained Plastic Surgeons and Dermatologists for the treatment of facial wrinkles and scars. Artecoll, the predecessor product to ArteFill, has been in widespread use in Europe, Canada, Mexico, South America and Asia since 1994 and used in over 250,000 patients. The company's product development is centered around its proprietary platform technology and formulations of injectable collagen and synthetic microspheres, which have potentially wide ranging applications as permanent bulking agents for soft tissue augmentation. ArteFill has been developed for the Plastic Surgery and Dermatology market. In addition, the company is in the process of establishing strategic partnerships to commercialize the development of (1) ArteSeal to seal and restore spinal disc injuries and for other orthopaedic applications including non-surgical connective tissue repair; (2) ArteFlux as a soft tissue bulking agent for the treatment of gastro-esophageal reflux disease (GERD GERD gastroesophageal reflux disease. GERD abbr. gastroesophageal reflux disease GERD ); and (3) ArteSure for the treatment of stress urinary incontinence stress urinary incontinence n. See stress incontinence. (SUI Sui (swā), dynasty of China that ruled from 581 to 618. This short-lived dynasty reunified China in 589 after 400 years of division and laid the foundation for further consolidation under the T'ang dynasty. ). ArteFill has received an approvable letter from the FDA, following successful completion of company-sponsored U.S. clinical trials. The company is in the process of establishing its San Diego-based GMP GMP (guanosine monophosphate): see guanine. manufacturing facility for the production of ArteFill and the portfolio of other development stage product candidates, including ArteSeal, ArteFlux and ArteSure. Artes Medical expects to begin marketing ArteFill to company-trained Plastic Surgeons and Dermatologists early next year. For more information about the company, technology platform and product development activities, visit the company's website www.artesmedical.com. Artes Medical, ArteFill, ArteSeal, ArteFlux and ArteSure are trademarks of Artes Medical USA, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion